Значение выявления микрометастазов в крови и костном мозге у больных раком молочной железы


Цитировать

Полный текст

Аннотация

Рак молочной железы (РМЖ) прочно удерживает первое место в структуре онкологической заболеваемости. Изучение феномена метастазирования продолжает оставаться актуальной задачейэкспериментальной и клинической онкологии, поскольку известно, что основной причиной смерти больных злокачественными заболеваниями чаще всего являются отдаленные метастазы. Благодаря успехам биохимии и молекулярной биологии в настоящее время в арсенале исследователей и клиницистов имеется огромное количество биологически значимых показателей, которые могут помочь в определении прогноза РМЖ и выборе терапии Приведенные данные указывают на то, что, скорее всего, обнаружение микрометастазов в костном мозге и периферической крови у больных РМЖ свидетельствует о высокой злокачественности процесса и дает возможность выделить группу больных с высоким риском рецидива. Кроме того, состояние костного мозга и периферической крови может использоваться для мониторинга больных, получающих химиотерапию, с целью оценки ее эффективности.

Об авторах

О Б Бжадуг

Российский онкологический научный центр им. Н.Н.Блохина РАМН

Н Н Тупицын

Российский онкологический научный центр им. Н.Н.Блохина РАМН

С А Тюляндин

Российский онкологический научный центр им. Н.Н.Блохина РАМН

Список литературы

  1. Давыдов М.И., Аксель Е.М. Злокачественные новобразования в России и странах СНГ в 2000 г.
  2. Dickson R.B, Lippman M.E. Molecular Basis of breast cancer. Molecular Basis of cancer, Second edition: 313-42.
  3. Kohn E.C, Liotta L.A. Metastasis and Angiogenesis: Molecular Dissection and Novel Application. Molecular Basis of cancer, Second edition: 163-71.
  4. Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местно - распространенного и метастатического рака молочной железы. 1997, с. 11-25.
  5. Моисеенко В.М. “Естественная история” роста рака молочной железы. Практическая онкология: избранные лекции. Под ред. С.А. Тюляндина и В.М. Моисеенко. 2004, с. 22.
  6. Fidler I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1996; 87:1588-92.
  7. Артамонова Е.В. Роль иммунофенотипирования опухолевых клеток в диагностике и прогнозе рака молочной железы. Автореферат дис. ... д - ра мед. наук. 2003.
  8. Rak J, Filmus J, Kerbel R.S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the “angiogenesis progression” hypothesis. Eur J Cancer 1996; 32A: 2438-50.
  9. Luzzi K.J, Mac Donald I.C, Schmidt E.E. Dormancy of Solitary Cells after Successful Extravasation and Limited Survival of Early Micrometastases. American Journal of Patholog 1998; 153:865-73.
  10. Naumov G, Mac Donald I, Weinmeister Р. Persistence of Solitary Mammary Carcinoma Cells in a Secondary Site. A Possible Contributor to Dormancy. Cancer Research 62,April 1, 2002; p. 2162-8.
  11. Fisher B, Osborn K, Margolese R et al. Neoplasms of the breast. Cancer medicine. 3d edition. Ed. By J. Holland et al. 1993; p. 1706-74.
  12. Гарин А.М. Адъювантная и неоадъювантная химиотерапия. Противоопухолевая химиотерапия. Справочник под ред. Н.И. Переводчиковой. 1996, с. 176-7.
  13. Тюляндин С.А. Системная терапия операбельного рака молочной железы. Практическая онкология: избранные лекции. Под ред. С.А. Тюляндина и В.М. Моисеенко. 2004, c. 73-83.
  14. Семиглазов В.Ф. Адъювантная химиотерапия рака молочной железы. Материалы IV Российской онкологической конференции. 2000; с 35-40.
  15. Schoenfeld A, Kruger K.N, Gomm J et al. The detection of Micrometastasis in the Peripheral Blood and Bone Marrow of patients with Breast Cancer Using Immunohistochemistry and reverse Transcriptase Polymerase Chain Reaction for Keratin 19. Eur J cancer, 199; 33(6): 854-61.
  16. Ikeda N, Miyoshi Y, Motomura K et al. Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA. Jpn J Cancer Res. 2000 Sep; 91(9):918-24.
  17. Jung Y, Lee K, Kim H et al. Clinical Significance of Bone Marrow Micrometastasis Detected by Nested RT-PCR for Keratin-19 in Breast Cancer Patients. Japanese Journal of Clinical Oncology 2003; 33:167-72.
  18. Gebauer G, Fehm T, Merkle E et al. Epithelial Cells in Bone Marrow of Breast Cancer Patients at time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up. J Clin Oncol 2001; 16: 3669-74.
  19. Gerber B, Krause A., Muller et al. Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors. J Clin Oncol 2001; 19: 960-71.
  20. Molino A, Pelosi G, Micciolo R et al. Bone marrow micrometastases in breast cancer patients. Breast Cancer Research and Treatment 58. 1999; 123-30.
  21. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high - risk breast cancer patients. J Clin Oncol 2000;18: 80-6.
  22. Diel I.J, Kaufmann M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer. A prognostic factor for distant metastasis. J Clin Oncol 10(10): 1992. (55)1534-9.
  23. Cote R.J, Rosen P.P, Lesser M.L et al. Prediction of early relapse in patients with operable Breast Cancer by the detection of occult Bone Marrow Micrometastasis. J Clin Oncol 1991; 9:1749-56.
  24. Coombes R.C, Berger U. Easton D et al. Prognostic significance of micrometastasis in Bone Marrow of patients with Primary Breast Cancer. Natl Cancer Inst Monogr 1986;1: 51-3.
  25. Janine L Mansi et al. Outcome of primary - breast - cancer patients with micrometastases: a long - term follow - up study. Lancet 1999; 354: 195-200.
  26. Funke I, Schraut W. Meta - analyses of studies on bone marrow micrometastasis: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16(2):557-66.
  27. Braun S, Cevatli S, Assemi C et al. Comparative analysis of Micrometastasis to the Bone marrow and Lymph Nodes of Node-Negative Breast Cancer Patients Receiving No Adjuvant therapy. J Clin Oncol 2001;19:5(March 1): 1468-75.
  28. Kasimir-Bauer S, Oberhoff, Slivinska K et al. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use? Breast Cancer Res. Treat. 2001; 69(2):123-32.
  29. Manhani A.R, Manhani R, Soares et al. CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res. Treat. 2001 Apr; 66(3):249-54.
  30. Zhang J, Shen K.W, Liu G et al. Antigenic profiles of disseminated breast tumour cells and microenvironment in bone marrow. Eur J Surg Oncol 2003 Mar; 29 (2): 121-126
  31. Klein C.A, Blankenstein T.J, Schmidt-Kittler O et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002 Aug 31; 360 (9334): 683-9.
  32. Schindlbeck C, Janni W, Schaffer P et al. Tumor biology of primary breast cancer and minimal residual disease. Acta Med Austriaca 2002; 29(Suppl 59): 27-31.
  33. Крохина О.В. Микрометастазы рака молочной железы в костный мозг. Иммуноморфологическая диагностика. Автореферат дис. ... канд. мед. наук. 2002.
  34. Zia A, Schildberg F.W, Funke I et al. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 2001 Aug 15; 93 (4): 566-70.
  35. Kasimir-Bauer S, Oberhoff C, Schindler A.E. A summary of two clinical studies on tumour cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review). Int J Oncol 2002 May; 20 (5): 1027-34.
  36. Перадзе Н.А. Бесцитокиновая мобилизация стволовых гемопоэтических клеток у больных раком молочной железы. Автореферат дис. ... кан. мед. наук. 2004.
  37. Thurm H, Ebel S, Kentenich et al. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res. 2003 Jul; 9 (7):2598-604.
  38. Mansi J.l, Easton D, Berger U et al. Bone Marrow Micrometastasis in Primary Breast Cancer: prognostic significance after 6 years follow - up. Eur J Cancer 1991; 27: 1552-5.
  39. Berger U, Bettelheim R, Mansi J.L et al. The relationship between micrometastasis in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 90, 1-6, 1994.
  40. Schlimok G, Funke I, Holzmann B, Gottinger G, Schmidt G, Hauser H, Swierkot S, Warnecke H.H et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti - cytokeratin and in vivo labeling with anti -17-1A monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1987, Dec; 84(23):8672-86.
  41. Wiedswang G, Borgen E, Karesen R et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003; 21(18): 3469-78.
  42. Kirk S.J, Cooper G.G, Hoper M et al. The prognostic significance of marrow micrometastases in women with early breast cancer. European J Surg Oncol 1990; 16: 481-5.
  43. Zia A, Schildberg F.W, Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 2001 Aug 15; 93(4):566-70.
  44. Offner S, Schmaus W, Witter K et al. p53 gene mutations are not required for early dissemination of cancer cells. PNAS 1999; 96(Issue 12): 6942-6.
  45. Muller P, Weckerman D, Riethmuller G et al. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytigenet 1996; 88: 8-16.
  46. Litle V.R, Lockett S.J, Palavicini M.G. Genotype/phenotype analyses of low frequency tumor cells using computerized image microscopy. Cytometry 1996; 23:244-349.
  47. Guba M, Cernaianu G, Koehl G.A Primary Tumor Promotes Dormancy of Solitary Tumor Cells before Inhibiting Angiogenesis. Cancer Research 2001, July 15; 61:5575-79.
  48. Ditsch N, Mayer B, Rolle M, Untch M. Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res 2003;162:141-7.
  49. Поддубная И.В. Лечение индолентных неходжкинских лимфом//Практическая онкология. 2004; Т.5. № 3 (19). С. 203-208.
  50. Braun S, Schlimok G, Heumos I et al. erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients. Cancer Research March 1, 2001; 61: 1890-5.
  51. Pantel K, Cote R, Fodstad J. Detection and Clinical Importance of Micrometastatic Disease. Journal of the National Cancer Institute July 7, 1999; 91(13): 1113-24.
  52. Cobleigh M. Cobleigh M.A, Vogel C.L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over - expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999: 17: 2639-264.
  53. Schlimok G, Pantel K, Loibner H et al. Reduction of metastatic carcinoma cells in bone marrow by intravenously administred monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer. 1995 Oct; 31A (11): 1799-803.
  54. Pantel K., Schlimok G., Kutter D.. Frequent down - regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Research, Vol 51, Issue 17, 47:12-5.
  55. Aerts J, Wynendaele W, Paridaens et al. A real - time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Annals of Oncology 2001; 12: 39-46.
  56. Kvalheim G, Naume B, Nesland J et al. Minimal residual disease in breast cancer. Cancer and Metastasis Reviews 1999; 18: 101-108.
  57. Cristofanilli M, Budd G, Ellis M et al. Circulating tumor cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine August 2004; 351: 781-91.
  58. Gafforio J.J, Serrano M.J, Sanches-Rovira P et all. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen - receptor status and predicts for poor prognosis. Int J Cancer 2003 Dec 20; 107 (6): 984-90.
  59. Giatromanolaki A, Koukourakis M, Kakolyris S. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004 Feb 10; 108(4): 620-7.
  60. Stathopoulou A, Vlachonikolis D, Mavroudis D et al. Molecular detection of Cytokeratin-19-Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance. J Clin Oncol 2002; 16: 3404-12.
  61. Smith B.M, Slade M.J, English J et al. Response of Circulating Tumor Cells to Systemic Therapy in Patients With Metastatic Breast Cancer: Comparison of Quantative Polimerase Chain Reaction and Immunocytochemical Techniques. J Clin Oncol 2000; 7: 1432-9.
  62. Xenidis N, Vlachonikolis I., Mavroudis D et al. Peripheral Blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann of Oncol 2003; 14: 849-55.
  63. Racila E., Euhus D., Weiss A.J. et al. Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. USA, 1998 April 14; 4589:45-94.

© ООО "Консилиум Медикум", 2004

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах